Gene · 2195
Papers4,590
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
961 to 980 of 4,590
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrative Analysis of ceRNA Networks in human periodontal ligament stem cells under hypoxia. | Oral Dis | 2023 | 34874587 | PubTator, text mining | PubMed |
| Use of expanded carrier screening for retrospective diagnosis of two deceased siblings with Van Maldergem syndrome 2: case report. | Asian Biomed (Res Rev News) | 2022 | 37551355 | PubTator, text mining | PubMed |
Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy. | Front Immunol | 2022 | 36818471 | PubTator, text mining | PubMed |
| Comparative genomic analysis of esophageal squamous cell carcinoma among different geographic regions. | Front Oncol | 2022 | 36741715 | PubTator, text mining | PubMed |
| Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients. | Front Oncol | 2022 | 36741696 | PubTator, text mining | PubMed |
| Development and validation of a GRGPI model for predicting the prognostic and treatment outcomes in head and neck squamous cell carcinoma. | Front Oncol | 2022 | 36713509 | PubTator, text mining | PubMed |
| [The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | 36709189 | PubTator, text mining | PubMed |
| [Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | 36709134 | PubTator, text mining | PubMed |
Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review. | Front Immunol | 2022 | 36703977 | PubTator, text mining | PubMed |
| Whole-genome characterization of large-cell lung carcinoma: A comparative analysis based on the histological classification. | Front Genet | 2022 | 36685819 | PubTator, text mining | PubMed |
| Relationships between Sclerostin, Leptin and Metabolic Parameters in Non-Dialysis Chronic Kidney Disease Males. | J Pers Med | 2022 | 36675692 | PubTator, text mining | PubMed |
| The Role of miRNAs, circRNAs and Their Interactions in Development and Progression of Hepatocellular Carcinoma: An Insilico Approach. | Genes (Basel) | 2022 | 36672755 | PubTator, text mining | PubMed |
| Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma. | Biomolecules | 2022 | 36671475 | PubTator, text mining | PubMed |
| Single-Cell Transcriptome Identifies Drug-Resistance Signature and Immunosuppressive Microenvironment in Metastatic Small Cell Lung Cancer. | Adv Genet (Hoboken) | 2022 | 36618022 | PubTator, text mining | PubMed |
| Repurposed Drugs in Gastric Cancer. | Molecules | 2022 | 36615513 | PubTator, text mining | PubMed |
| Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) for Immunomodulation in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS). | J Clin Med | 2022 | 36615103 | PubTator, text mining | PubMed |
| Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells. | Cancers (Basel) | 2022 | 36612206 | PubTator, text mining | PubMed |
| Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review. | Medicine (Baltimore) | 2022 | 36595763 | PubTator, text mining | PubMed |
| Insights on Carbon Neutrality by Photocatalytic Conversion of Small Molecules into Value-Added Chemicals or Fuels. | Acc Mater Res | 2022 | 36583010 | PubTator, text mining | PubMed |
| Primary central nervous system CD20-negative diffuse large B-cell lymphoma: a case report. | BMC Neurol | 2022 | 36581860 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2195/papers?page=49